{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219529","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-05-12T20:21:01+00:00","discovered_at":"2026-05-12T20:22:00.236853+00:00","generated_at":"2026-05-12T20:24:25.449006+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LB Pharma Q1 net loss $19.1M; cash $365.6M; Phase 3 schizophrenia trial launched","bullets":["Net loss of $19.1M in Q1 2026 vs $5.3M in Q1 2025; R&D expenses rose $11.2M to $14.6M.","Cash, equivalents, and marketable securities totaled $365.6M as of March 31, 2026; runway into Q2 2029.","Initiated pivotal Phase 3 NOVA-2 trial of LB-102 in acute schizophrenia; topline data H2 2027.","Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; topline expected Q1 2028.","Completed $100M private placement in Feb 2026; Phase 2 in adjunctive MDD planned early 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219529","json":"https://secwatch.observer/filing/0001193125-26-219529.json","markdown":"https://secwatch.observer/filing/0001193125-26-219529.md","text":"https://secwatch.observer/filing/0001193125-26-219529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/0001193125-26-219529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/d134118d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:24:25.449006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b3fa70ded6d8996bf9edc4cb6e08f56bca649f2","claim":"LB PHARMACEUTICALS INC reported financial results for the first quarter ended on March 31, 2026.","evidence_excerpt":"On May 12, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526219529/0001193125-26-219529-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended on March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}